Pieris AG – Product Pipeline Review – Q2 2011

Document Sample
Pieris AG – Product Pipeline Review – Q2 2011 Powered By Docstoc
					            Pieris AG – Product Pipeline Review – Q2 2011
                                                                                          Reference Code: GMDHC1296CDB

                                                                                               Publication Date: JULY 2011




Pieris AG – Product Pipeline Review – Q2 2011                                              GMDHC1296CDB / Published JULY 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Pieris AG – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                      2
List of Tables                                                                                                         4
List of Figures                                                                                                        4
Pieris AG Snapshot                                                                                                     5
    Pieris AG Overview                                                                                                 5
    Key Information                                                                                                    5
    Key Facts                                                                                                          5
Pieris AG – Research and Development Overview                                                                          6
    Key Therapeutic Areas                                                                                              6
Pieris AG – Pipeline Review                                                                                            8
    Pipeline Products by Stage of Development                                                                          8
    Pipeline Products – Monotherapy                                                                                    9
Pieris AG – Pipeline Products Glance                                                                                  10
    Pieris AG Clinical Stage Pipeline Products                                                                        10
         Phase I Products/Combination Treatment Modalities                                                            10
    Pieris AG–Early Stage Pipeline Products                                                                           11
         Pre-Clinical Products/Combination Treatment Modalities                                                       11
         Discovery Products/Combination Treatment Modalities                                                          12
Pieris AG – Drug Profiles                                                                                             13
    Angiocal                                                                                                          13
         Product Description                                                                                          13
         Mechanism of Action                                                                                          13
         R&D Progress                                                                                                 13
    PRS-010                                                                                                           14
         Product Description                                                                                          14
         Mechanism of Action                                                                                          14
         R&D Progress                                                                                                 14
    PRS-055                                                                                                           15
         Product Description                                                                                          15
         Mechanism of Action                                                                                          15
         R&D Progress                                                                                                 15
    PRS-060                                                                                                           16
         Product Description                                                                                          16
         Mechanism of Action                                                                                          16
         R&D Progress                                                                                                 16
    PRS-080                                                                                                           17
         Product Description                                                                                          17
         Mechanism of Action                                                                                          17
         R&D Progress                                                                                                 17
    PRS-110                                                                                                           19
         Product Description                                                                                          19
         Mechanism of Action                                                                                          19
         R&D Progress                                                                                                 19
    PRS-060                                                                                                           20
         Product Description                                                                                          20
         Mechanism of Action                                                                                          20




Pieris AG – Product Pipeline Review – Q2 2011                                             GMDHC1296CDB / Published JULY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                              Page(2)
Pieris AG – Product Pipeline Review



         R&D Progress                                                                                                 20
Pieris AG – Pipeline Analysis                                                                                         21
    Pieris AG – Pipeline Products by Therapeutic Class                                                                21
    Pieris AG - Pipeline Products By Target                                                                           23
    Pieris AG – Pipeline Products by Route of Administration                                                          24
    Pieris AG – Pipeline Products by Molecule Type                                                                    25
Pieris AG – Recent Pipeline Updates                                                                                   26
Pieris AG - Dormant Projects                                                                                          27
Pieris AG – Locations And Subsidiaries                                                                                28
    Head Office                                                                                                       28
Financial Deals Landscape                                                                                             29
    Pieris AG, Deals Volume Summary, 2004 to YTD 2011                                                                 29
    Pieris AG, Deals Summary By Region, 2004 to YTD 2011                                                              30
    Pieris AG, Deals Summary, 2004 to YTD 2011                                                                        31
    Pieris AG Detailed Deal Summary                                                                                   32
         Venture Financing                                                                                            32
         Pieris Secures $38 Million In Series B Financing                                                             32
         Pieris Secures $11.81 Million In Series A Financing                                                          35
         Pieris Enters Into Co-Development Agreement With Allergan                                                    37
         Pieris Enters Into Research Agreement With Pepscan Therapeutics                                              38
         Pieris Enters Into Research Agreement With GE Healthcare                                                     39
         Pieris Enters Into Collaboration Agreement With Syngenta                                                     40
         Licensing Agreements                                                                                         41
         Pieris Enters Into Licensing Agreement With Allergan                                                         41
Appendix                                                                                                              43
    Methodology                                                                                                       43
         Coverage                                                                                                     43
         Secondary Research                                                                                           43
         Primary Research              
				
DOCUMENT INFO
Description: Pieris AG – Product Pipeline Review – Q2 2011 Summary Global Market Direct’s pharmaceuticals report, “Pieris AG - Product Pipeline Review - Q2 2011” provides data on the Pieris AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Pieris AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Pieris AG and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Pieris AG - Brief Pieris AG overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Pieris AG human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Pieris AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Pieris AG’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Pieris AG’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Pieris AG in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Pieris AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnersh
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries